Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Helix BioPharma ( (TSE:HBP) ).
Helix BioPharma Corp. announced the filing of its unaudited interim financial statements for the three and six-month periods ending January 31, 2025. This filing includes the management’s discussion and analysis and certifications from the CEO and CFO. The release of these financial statements is a routine disclosure that provides stakeholders with insights into the company’s financial health and operational progress, potentially impacting investor confidence and market positioning.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing novel therapies to treat hard-to-treat cancers. The company has a diverse pipeline of drug candidates, including its lead candidate, Tumour Defence Breaker L-DOS47, which targets CEACAM6-expressing solid tumors. Helix is listed on multiple stock exchanges, including TSX, OTC PINK, and FWB.
YTD Price Performance: 1.12%
Average Trading Volume: 2,042
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$47.72M
For a thorough assessment of HBP stock, go to TipRanks’ Stock Analysis page.